Francisco del Val, recently nominated general manager of the business unit Sanofi Genzyme and country head of Sanofi Portugal, has two decades’ experience in the pharma industry. In his first interview in Portugal, Francisco shares with us his priorities and his vision, highlighting the importance of diversification, and innovation through Sanofi’s exciting new pipeline.
“Our affiliate tripled its activity in R&D in last 3 years: going from 8 studies in 2015 to 18 in 2018 and we have also increased the team. Five clinical studies have just been introduced in the first semester of this year."
